PH II study of adjuvant tx with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors > 4cm) IIA IIB and select IIIA [T3N1 T4N0-1] resected NSCLC and the clearance of (ctDNA)
Brief description of study
The purpose of the study is to determine and estimate the percentage of patients with undetectable circulating tumor DNA (ctDNA) after 4 cycles of adjuvant chemotherapy + Atezolizumab plus up to 13 additional cycles of Atezolizumab in patients with stage I (tumors = 4cm), IIA, IIB, and select IIIA [T3N1-2, T4N0-2] NSCLC who have detectable ctDNA after surgery, but prior to adjuvant therapy.
Clinical Study Identifier: s21-00482
ClinicalTrials.gov Identifier: NCT04367311
Principal Investigator:
Elaine Shum.
Other Investigators:
Joshua K Sabari,
Samantha VanMaanen,
Abraham Chachoua,
Elka R Travis,
Jessica Wang,
Vania R. Baudin,
Salman Rafi Punekar,
Sally Lau,
Christy Lynn Spalink,
Danny Perlaza,
Marissa Rybstein,
David Mendoza,
Melissa L Martinez,
James Newman,
Jeffrey G Schneider,
Avital Benson,
Natalia Cherkassky,
Monica Rivera,
Vamsidhar Velcheti.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
